右丙亚胺预防吡柔比星对心脏毒性作用的前瞻性研究被引量：4

下载PDF

导出

摘要目的观察右丙亚胺(Dexrazoxane,DEX)在以吡柔比星(Pirarubicin,THP)为主的恶性淋巴瘤治疗中对心脏保护作用及其毒副作用。方法收集2013年3月-2014年2月我科收治的诊断为淋巴瘤的初治患者50例,采用完全随机的方法分成两组,观察组25例使用DEX+含THP方案组,对照组25例THP方案组。记录患者化疗前及化疗后的一般情况及治疗反应,分别在化疗前,化疗3周期后,化疗4-6周期后进行心电图,行心脏超声心动图及左室射血分数,血肌钙蛋白等检查。结果通过化疗前,化疗3周期后两组进行比较,3方面比较差异均无显著性意义。通过化疗前、化疗4-6周期后两组进行比较,在肌钙蛋白检查,心电图检查方面(P>0.05),差异无显著性意义;左室射血分数比较(P<0.05),差异有显著性意义,血液学毒副作用方面,因化疗后常规G-CSF支持,结果两组在白细胞及中性粒细胞的降低比较(P>0.05),差异均无显著性意义。血小板降低观察组有加重趋向(P<0.05),差异有显著性意义。恶心、呕吐及脱发、乏力、肾功能损伤等不良反应两组无明显差异。结论吡柔比星有剂量累积性心脏毒性,右丙亚胺是吡柔比星的有效的心脏保护剂,能够降低心脏不良反应,提高吡柔比星继续治疗的可能性。

作者刘小梅黄韵红

机构地区江西省九江市第三人民医院肿瘤科贵州省肿瘤医院淋巴瘤科

出处《江西医药》 CAS 2016年第3期246-249,共4页 Jiangxi Medical Journal

关键词霍奇金淋巴瘤非霍奇金淋巴瘤右丙亚胺吡柔比星

分类号 R969 [医药卫生—药理学]

引文网络
相关文献

参考文献14

1Zhao Xian ying, zhang tao, liu yi min. Dexrazoxane for anthracycline antitumor antibiotics heart protection study progress [J]. Cancer Chinese, 2001,20(4) :439-440.
2杨朝英.THP-COP方案治疗老年病人NHL的优越性[J].广东微量元素科学,2005,12(9):19-22. 被引量：2
3Hortobagyi GN1,Theriault RL,Frye D,et al. Pirarubicin in combination chemotherapy for metastatic breast cancer [J]. Am J Clin Oncol, 1990,13(1)1:54-56.
4Dhingra K1,Frye D,Newman RA,et al. Phase II clinical and pharmacological study of pirarubicin in combination with 5- fluorouracil and cyclophosphamide in metastatic breast cancer[J]. Clin Cancer Res, 1995,1(7) :691-697.
5Cvetkovic RS,Scott LI. Dexrazoxane:a review of its use for cardioprotection during anthraeycline chemotherapy [J]. Drugs, 2005,65(7) : 1005-24.
6AlbiniA,Pennesi G,Donatelli F,et al. Cardiotoxieity of anticaneer drugs:the need for cardio-oncology and cardio-oncological prevention[J]. JNatlCaneerlnst, 2010,102(1): 14-25.
7Marty M,Espei, M, Llombart A, et al. Multicenter randomized phase III study of the cardioproteetive effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy [J]. Annals of Oncology,2006, 17(4) :6!4-622.
8LipshultzSE ,SculIyRE ,LipsitzSR,et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high- risk acute lymphoblastic leukaemia :long -term follow-up of a prospective,randomised, multicentre trial [J]. Lancet Oncol, 2010, 11 (10) : 950-961.
9蔡旭镇,黄丽娜,陈俊鹏,林春平.右丙亚胺对表柔比星所致心脏毒性防治作用的观察[J].今日药学,2013,23(1):43-45. 被引量：5
10Koh E,Nakamum T,TakahashlH,et al. Tropor-n-T and brain hatriuretic peptide as pre-dictors for adriamyein-induced cardiomyopathy in rats[J]. Cite J,2004,68(2) : 163-167.

二级参考文献27

1江泽飞,宋三泰.蒽环类化疗药物治疗乳腺癌的新动向[J].中华肿瘤杂志,2005,27(4):193-195. 被引量：27
2徐兵河,赵龙妹,王佳玉,袁芃.泰索帝联合顺铂治疗31例蒽环类耐药性晚期乳腺癌疗效分析[J].中华肿瘤杂志,2006,28(6):471-473. 被引量：46
3Okuma K.Acute cardiotoxicity of anthracyclines-analysis by using Holter ECG[J].Gan To Kagaku Ryoho,1984,11(4):902-911.
4Mathe G,Umezawa H,Umezawa K,et al.Minimal cardiotoxicity of THP-Adriamycin(Pirarubicin)in hamsters and in cancer patients,its greater cardiac tolerance compared to other antharacyclines[A].In:Kuemmerle H P,ed.Advance in Experimental and Clinical Chemotherapy 15th International Congress of Chemotherapy(Workshop on Pirarubicin,July 19-24,1987)[C].Turky:Lands-berg/lech Ecomed,1988.35-46.
5Tominaga T.A randomized controlled study of 2R-4'-O-trtrahydropyranyl adriamycin and adriamacin in combination with cyclophos-phamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer(Clinical Study Group of THP Bbreast Cancer in Japan)[J].Biomed Pharmacother,1989,43(4):271-278.
6Herait P.THP-adriamycin:status of the clinical development of a new anthracycline in France[J].Pathol Biol (Paris),1990,38(1):64-68.
7Jemal A,Siegel R,Ward E. Cancer statistics,2008[J].CA:A Cancer Journal for Clinicians,2008.71-96.
8Barry E,Alvarez JA,Scully RE. Anthracycline-induced cardiotoxicty:course,pathophysiology,prevention and management[J].Expert Opinion on Pharmacotherapy,2007.1039-1058.
9Lipshultz SE,Alvarez JA,Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer[J].Heart,2008.525-533.
10Marty M,Espié M,Llombart A. Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline based chemotherapy[J].Annals of Oncology,2006.614-622.